
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : The collaboration will leverage PostEra's AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen's drug discovery expertise, to advance up to 5 small molecule programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 16, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery Platform
Sponsor : National Institutes of Health
Deal Size : $68.0 million
Deal Type : Funding
Details : ASAP will use PostEra's end-to-end AI-first approach to accelerate the discovery process, generating molecules with optimised properties, designing rapid synthesis, and optimally prioritising experiments.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 18, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery Platform
Sponsor : National Institutes of Health
Deal Size : $68.0 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Breyer Capital
Deal Size : $24.0 million
Deal Type : Series A Financing
PostEra Closes $24M in New Financing to Advance Drug Discovery
Details : PostEra will use the proceeds to advance a series of partnered drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Breyer Capital
Deal Size : $24.0 million
Deal Type : Series A Financing
